Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 – Daily Science

By Stem Cell Medicine

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

Make an Inquiry before Buying:https://www.trendsmarketresearch.com/checkout/11723/Single

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Request for Report Discount:https://www.trendsmarketresearch.com/report/discount/11723

Link:
Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 - Daily Science

15 Good News Stories To Tackle The COVID-19 Sadness – IFLScience

By Stem Cell Medicine

For Earth, bleak times lay ahead. TheCOVID-19 diseaseis known to cause respiratory illness and fever, but some extra symptoms sweeping across the globe right now seem to be stress, fear, and anxiety. To provide some light relief in these dark times, weve collated 15 of our favorite good news stories to remind you that not everything is awful. Hold tight everybody, 2021 will come eventually.

The Super Pink Moon is comingYou might be stuck at home as part of your self-isolation, but luckily the night sky is about to put on quite a show as April sees the return of the Super Pink Moon. Full moons happen every month and were given different names by the Native Americans to map out the year based on significant events that ran in tandem with the occurrence of a full Moon. Aprils is known as the pink moon because it appeared at the same time as pink spring flowers. This Aprils will be a Super Pink Moon as it is the second supermoon of the year, a term used to describe the slightly enlarged appearance of the Moon as its fully illuminated by the Sun due to Earths position between the two. Quarantine or no, if you've got access to a window you should be able to catch sight of this beauty on April 7 and when you do, think of all the other people looking up at the same moon. Self isolation doesn't mean you're alone.

Mice have been cured of diabetesAn astonishing discovery at the Washington University School of Medicine in St. Louis has revealed that human stem cells could be successfully engineered to cure diabetes in mice, offering an avenue of hope for the treatment of this debilitating disease. They used human pluripotent stem cells, cells that have the capacity to become any cell in the body, to create insulin-producing pancreatic beta cells. The engineered stem cells supplemented the diabetic mices inability to produce insulin, curing them of the disease for 9 months to a year before relapse occurred.

Theres a new green fuel in townHydrogen fuel was fast shaping up to be a hopeful route for a zero-emissions means of running things, but its costly production in terms of energy was affecting hopes for it being a sustainable resource. A team in Tokyo has now managed to refine the process to yield 25 times more hydrogen than previous methods all while using thrifty ingredients including light and a specific kind of rust. Combined with all the solar power breakthroughs currently occurring, green energy is on the up.

A crash course in what not to do, according to one Stanford University psychologist.

Babies love baby talkEven if it makes your skin crawl to hear adults cooing over little uns, it turns out babies across the globe are universally partial to baby talk. The news comes fromStanford psychologist Michael Frank who led the largeststudyto date looking at how the different ways adults speak is received by babies across the world. While all babies were fans, older babies liked it best and even showed a preference for baby talk in their native language as they likely recognized it most even if they couldnt speak it yet. The overall winner was oohs and coos, so think twice before scorning your new-parent friends for embarrassing you in public the babies have spoken.

Important change in the winds for HIV treatmentShortly after a UK man became the second person cured of HIV a fantastic breakthrough in the treatment of this once devastating disease theres more good news in the UK as PrEP, a preventative drug that prevents HIV infection, will finally be available nationwide on the NHS having already been made available in Scotland. After a 3-year study involving 20,000 participants, the drug will be made available to those at higher risk of exposure from April. PrEP is already available in the US and you can find PrEP providers near you here.

-

Plasters finally take a step towards racial inclusivityMajor UK superstore Tesco has taken the long-awaited step to introduce skin tone diversity into their range of bandaids. Previously, widely available bandaids, or plasters in the UK, have mainly catered to Caucasian individuals and the racial oversight was brought to light by a moving Tweet from Domonique Apollon in April 2019 after he wore a bandaid suitable for his skin tone for the first time. Longtime readers of Malorie Blackman's literary series Noughts and Crosseswill appreciate this poignant detail becoming a reality, as will those watching the current BBC dramatization available to watch via iPlayer in the US (excellent for those self-isolating).

Universal flu vaccine passes integral stageWatchers of the Pandemic documentary on Netflix (we wouldnt recommend catching up now if you missed it) may remember the plight of flu-fighting epidemiologists as the constantly shape-shifting nature of influenza meant strains were annually moving beyond existing vaccinations. Now, a universal vaccine is becoming a reality as for the first time a vaccine, called FLU-v, has been developed that can induce immune responses that last at least six months. Phase I and II of the clinical trial have been approved meaning its safety for use in human subjects and we hotly await what comes next for the groundbreaking vaccine.

Top marks for lights out in dark sky nationSometimes a bit of darkness can be a good thing, and when it comes to nighttime, the tiny South Pacific island of Niue tops the charts. The International Dark-Sky Association (IDA) is a non-profit working to protect our most precious natural spaces from light pollution, and this year chose Niue as the first entire country ever to be accredited as a Dark Sky Place. This classification recognizes responsible lighting policies that preserve the natural darkness of nighttime carrying with it endless benefits for the biological cycles of animals, plants and humans.

-

People hating on National Parks created beautiful artIn a glimmering example of you cant please everybody, artist Amber Share decided to take some of the best worst reviews of National Parks in America and turn them intotourism posters, showing that we can still make something funny in the face of people's negativity. You can see the whole collection on her Instagram account @subparparks, but a personal favorite has to be the above magnificent minimization of Yellowstone.

CRISPR may hold the key for curing genetic blindnessSurgeons at Oregon Health & Science Institute have attempted to use gene hacking to cure Leber congenital amaurosis, a genetic condition that leads to the onset of blindness in early childhood. By directly gene editing within the patients eye, researchers hope to ...take people who are essentially blind and make them see," according to researchers.

The Arctic seed vault in Svalbard is thrivingLast month saw an enormous glut of 60,000 seed samples added to the ever-growing collecting in the Svalbard Global Seed Vault. Tucked beneath a mountain in Norway's Svalbard archipelago, the initiative began with hopes to create a Noahs ark for plant diversity to protect our green spaces should a global catastrophe occur up top. The collection now includes 1.05 million seed varieties including the first-ever donation from an indigenous US tribe. Nicknamed the "Doomsday vault", we may need it sooner than thought.

Sea sponges can sneeze, and the footage is amazingThe aah and choo of asneezing sea spongehas been caught on camera for the first time and the recording is hilarious. Stumbled upon almost by accident, the discovery came about while researchers were observing sea cucumbers and sea urchins sniffing the sea floor. The video shows the two-part sneeze of a tulip-shaped sponge as it expands before contracting, expelling particles as it goes. Researchers arent yet sure what the sneezes are in response to. Lets hope its not a case ofthe suds.

Vernal equinox brings early springThe times might be dark but for the Northern hemisphere, the days wont be, as spring arrives on March 19, the earliest date in 124 years. The variation in the date is the result of leap years and daylight savings time. It should be noted this is the astronomical definition of spring, which refers specifically to the position of Earth's orbit in relation to the Sun, so perhaps dont expect to hear a gay little spring song in your garden just yet.

Its possible some dinosaurs could GLOW IN THE DARKA titillating discovery published in the journal Historical Biology recently revealed that some dinosaurs may have glowed in the dark thanks to ultraviolet fluorescing feathers and horns. Many extant bird species are tetrachromats, defined by a fourth cone in their retina that means they can see the UV spectrum. Co-author Jamie Dunning's work on the photoluminescence of puffin beaks under UV light inspired the questions, could dinosaurs have this too? We'd like the answer to be yes, please. The only thing cooler than dinosaurs is glow-in-the-dark dinosaurs.

If you need more positivity in your life right now, take a look at these ingenious social distancing moments from around the world that will restore your faith in humanity.

More:
15 Good News Stories To Tackle The COVID-19 Sadness - IFLScience

Analyzing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) – Redmond Register

By Stem Cell Medicine

CRYO-CELL International (OTCMKTS:CCEL) and Harsco (NYSE:HSC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation and Earnings

This table compares CRYO-CELL International and Harscos revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for CRYO-CELL International and Harsco, as provided by MarketBeat.com.

Harsco has a consensus price target of $26.67, suggesting a potential upside of 325.99%. Given Harscos higher probable upside, analysts clearly believe Harsco is more favorable than CRYO-CELL International.

Volatility & Risk

CRYO-CELL International has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Harsco has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Profitability

This table compares CRYO-CELL International and Harscos net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.3% of CRYO-CELL International shares are owned by institutional investors. Comparatively, 92.2% of Harsco shares are owned by institutional investors. 54.0% of CRYO-CELL International shares are owned by company insiders. Comparatively, 1.8% of Harsco shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Harsco beats CRYO-CELL International on 8 of the 12 factors compared between the two stocks.

CRYO-CELL International Company Profile

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.

Harsco Company Profile

Harsco Corporation provides industrial services and engineered products worldwide. The company operates in three segments: Harsco Metals & Minerals, Harsco Industrial, and Harsco Rail. The Harsco Metals & Minerals segment provides on-site services of material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; and value added environmental solutions for industrial co-products, as well as produces industrial abrasives and roofing granules. The Harsco Industrial segment manufactures and supplies custom-engineered and manufactured air-cooled heat exchangers for the natural gas, natural gas processing, and petrochemical industries; industrial grating products, such as metal bar grating configurations for industrial flooring, and safety and security applications in the energy, paper, chemical, refining, and processing industries. It also offers heat transfer products, such as boilers and water heaters for commercial and institutional applications; and high-security fencing products. The Harsco Rail segment designs and manufactures safety systems for transportation and industrial applications; and equipment, after-market parts, and services for the maintenance, repair, and construction of railway track. It serves private and government-owned railroads, and urban mass transit systems. Harsco Corporation was founded in 1853 and is headquartered in Camp Hill, Pennsylvania.

Receive News & Ratings for CRYO-CELL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRYO-CELL International and related companies with MarketBeat.com's FREE daily email newsletter.

Original post:
Analyzing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register

Immatics and Molmed become the subjects of very different deals – Vantage

By Stem Cell Clinic

How do companies seal a deal when executives cannot shake hands? Maybe the management teams of Arya Sciences and Immatics bumped elbows when the latter was bought by the blank cheque company on Tuesday in a deal worth $252m. As for the Japanese group AGCs 240m ($267m) offer for Italys Molmed, presumably execs could not meet in person at all given that Italy is still locked down.

Be that as it may an acquisition and a bid have been arranged somehow, proving that though the Covid-19 pandemic has had a deadening effect on deal-making it has not annihilated it altogether. The interesting aspect is how Immatics and Molmed both cell therapy players, albeit of different kinds will develop from here.

A stark mission

Arya Sciences Acquisition Corp was set up to do what its name suggests: its sole purpose is to effect a merger or similar combination with one or more businesses. It is controlled by the hedge fund Perceptive Advisors, and floated on Nasdaq in October 2018, raising $144m.

Immatics will receive $148m of cash from Aryas trust account, which holds the IPO proceeds plus interest, when the deal closes in the second quarter. Perceptive and other institutional investors, including Redmile and Wellington Partners, have committed a further $104m more in pipe funding.

Arya saysImmatics T-cell receptor-based candidates for solid tumours hold the kind of disruptive potential the investment vehicle was looking for. Immatics has two main product classes, adoptive cell therapies, which use natural or engineered T cells against cancer, and T-cell receptor bispecifics, which bind to tumour-specific peptides and to immunomodulating T-cell surface proteins.

Gaining access to the US capital markets will allow Immatics to advance its projects through the clinic. The group expects topline phase I/II data from three TCR projects and one bispecific by the end of this year.

Going public represents a long-held goal for Immatics. The company was already eyeing the US exchanges two years ago (Why Immatics could soon become the next listed cell therapy player, July 16, 2018).

Long term

Molmed could take a very different route if AGCs bid for it is accepted, becoming a part of a much larger whole. Japans AGC is the largest glass company in the world, but is also active in the fields of ceramics, electronics and chemicals.

AGC considers its life sciences business a strategic priority, and aims to get the units sales above 100bn by 2025. Buying Molmed it is offering 0.518 per Molmed share, at a premium of 110% will allow ACG to move into gene and cell therapies.

It will not get there fast. Molmed withdrew Zalmoxis, designed to reduce the risk or rejection of an imperfectly matched stem cell transplant, from sale in Europe after a confirmatory phase III trial failed last summer. Its next most advanced product is its Car-T project CAR44v6, in a phase I/II trial for acute myeloid leukaemia and multiple myeloma. This looks unlikely to yield data before 2023.

Molmed does have another string to its bow that could appeal to AGC: it is the first company in Europe to have obtained GMP manufacturing authorisation for cell and gene therapies ex vivo, and offers this to other groups. For example, it produces Strimvelis, Orchard Therapeutics gene therapy for the immunodeficiency disorder ADA-SCID.

Closure is odds-on, since Molmeds largest shareholder, Fininvest the holding company of the family of the former Italian prime minister Silvio Berlusconi has agreed to tender its 23% stake. Hopefully, in buying this very specialised company, AGC knows what it is doing.

Here is the original post:
Immatics and Molmed become the subjects of very different deals - Vantage

Claudia Rodrigues is removed from the clinic where she was hospitalized because of the coronavirus – Crypto Dictation

By Stem Cell Clinic

The new coronavirus is spreading all over the world and, after arriving in Brazil, has changed the lives of most Brazilians. The government's recommendation is that people stay at home and take all recommended hygiene care, thus preventing the virus from spreading in the country.

The greatest concern of the government is with the people who are part of the group considered at risk, which are the elderly and people who already have some type of chronic disease. These people are the ones most likely to have complications if they become infected with the virus.

Actress Claudia Rodrigues is one of those people who are part of the risk group and who must have redoubled health care so that it does not become contaminated with covid-19. The actress has been battling multiple sclerosis for 20 years, which is an autoimmune disease that affects the central nervous system.

The actress has already been hospitalized several times in a serious condition in times of crisis of multiple sclerosis and at the moment was hospitalized in a clinic in the state of So Paulo, following the autoimmune treatment.

Due to government recommendations and fearing contamination by covid-19, the actress was taken home.

The treatment that actress Claudia Rodrigues performed at the clinic in So Paulo is very delicate, due to her health condition in relation to multiple sclerosis, and for that reason, extra care is needed with the artist, as she already has low immunity due to disease.

Due to the situation faced by the actress, her doctors and family members chose to redouble the artist's health care and for this very reason, they decided that it was better that she be taken home and that she should remain in isolation at her residence.

Adriane Bonato, who is Claudia Rodrigues' businesswoman, revealed that the actress is at her home and that she is performing exercises on the spot. The businesswoman reaffirmed that the artist has low immunity due to having undergone stem cell transplantation and that, for this very reason, she runs a very high risk in relation to the new virus.

According to Adriane, Claudia Rodrigues will remain at home for the next 30 days, preventing herself from being infected by the new coronavirus.

Like most Brazilians, many Celebrity are at home complying with government resolutions on social isolation to prevent the mass spread of the new coronavirus. Many artists are taking advantage of the large number of followers in their profiles to try to make the population aware of the importance of following the recommendations of the Ministry of Health and especially the recommendation to be quarantined at home.

Big names like Luciano Huck, Ana Maria Braga and many others have posted videos asking Brazilians for empathy and to remain in social isolation. The artists Preta Gil and Fernanda Paes Leme, who were diagnosed with the disease, are sharing their experiences with the new coronavirus. They are keeping followers informed about how the isolation is going and the symptoms they are feeling about the coronavirus.

Don't miss our Facebook page!

ALL RIGHTS RESERVED

Read the rest here:
Claudia Rodrigues is removed from the clinic where she was hospitalized because of the coronavirus - Crypto Dictation

Stem Cell Therapy Market 2020 Demand with Global Forecast by Top Leading Players: Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co.,…

By Stell Cell Research

New Jersey, United States: A qualitative research study accomplished by Verified Market Research titled 2020-2026 Global and Regional Stem Cell Therapy Market: Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report is the most up to date report which comprises the latest trends that influence the market competition in the forecast period from 2020 to 2026. The report presents different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. Primarily, the report introduces market demands and the present position of the Stem Cell Therapy market.The report completes the value chain and downstream and upstream essentials.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. The growth potential, market share, size, and prospects of each segment and sub-segment are portrayed in the report. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Stem Cell Therapy Market.

A number of leading manufacturers mention in the Stem Cell Therapy Market research report are focusing on expanding operations in regions, as they exhibit potential business opportunities. The Stem Cell Therapy Market report classifies the market dynamics and trends in the global and regional market considering several aspects including technology, supplies, capacity, production, profit, and price.

Stem Cell Therapy Market: Research Methodology

1. Primary Research:

2. Secondary Research:

During our Secondary research, we collect information from different sources such as databases, regulatory bodies, gold and silver-standard websites, articles by recognized authors, certified publications, white papers, investor presentations and press releases of companies, and annual reports.

Data collection module is used for data collection and analysis of the base year. The market data is analyzed and estimated using statistical models and systematic market. The main research methodology used for the preparation of reports, including data mining, primary (industry experts) validation and top-down analysis, market overview and guidance, the company market share analysis, measurement standards, and analysis of the stock sellers.

Vendor Competitive Analysis:

The report focuses on the strategies considered by the market participants to gain a major share in the Stem Cell Therapy market. Through this, the competitors will get an overview of the competitive landscape so they can make business decisions. Leading players working in the global market are analyzed with their company information, product profile, product specification, picture, capacity, production, price, cost, global investment plans, and supply-demand scenarios.

Stem Cell Therapy Market Regional Coverage

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Ask For Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=PN24&utm_medium=002

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=PN24&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Business Opportunities and Stem Cell Therapy Market Outlook

Continued here:
Stem Cell Therapy Market 2020 Demand with Global Forecast by Top Leading Players: Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co.,...

Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights – BioSpace

By Stell Cell Research

MENLO PARK, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Forty Seven Inc., (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.

In 2019, Forty Seven transformed into a multi-asset, late-stage development company with clear paths to registration in two distinct, underserved patient populations. In parallel, we entered into several new partnerships designed to accelerate the development of magrolimab and FSI-174, and allow us to evaluate both compounds more rapidly across a range of indications and combination paradigms, said Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of Forty Seven. Following the recently announced acquisition by Gilead, and with the benefit of their resources and capabilities, we are even better positioned to build on this momentum and deliver on our foundational vision of developing novel immunotherapies that help patients defeat their cancers.

Dr. McCamish continued, Like so many others, we are closely monitoring COVID-19, and have recently instituted a number of proactive measures to mitigate the spread of the virus and protect the safety, health and well-being of the patients, families and healthcare professionals involved in our clinical development programs, as well as our employees. While we are working diligently to limit the impact of COVID-19 on our ongoing clinical trials, we, together with our contract research organization, decided to delay the initiation of our Phase 1 trial of FSI-174 in healthy volunteers in order to support physicians and hospitals in devoting their resources to treating COVID-19 patients, and avoid exposing healthy volunteers to unnecessary risk. We will continue to evaluate the pandemic and expect to re-visit the timing of potential trial initiation in the second quarter.

Fourth Quarter and Recent Business Highlights:

Magrolimab Clinical Programs:Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Diffuse Large B Cell Lymphoma (DLBCL)

Solid Tumors

FSI-174:

FSI-189:

Corporate:

Fourth Quarter and Full Year 2019 Financial Results:

About Forty Seven, Inc.Forty Seven, Inc.is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed fromStanford University. Forty Sevens lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a dont eat me signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia and non-Hodgkins lymphoma. In March 2020, Forty Seven entered into a definitive agreement to be acquired by Gilead Sciences, Inc., which is expected to close during the second quarter of 2020.

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Forty Seven, nor is it a substitute for any tender offer materials that Gilead, its acquisition company or Forty Seven has or will file with the SEC. A solicitation and an offer to buy shares of Forty Seven will be made only pursuant to an offer to purchase and related materials that Gilead has filed with the SEC. At the time the tender offer was commenced, Gilead filed a Tender Offer Statement on Schedule TO with the SEC, and Forty Seven filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. FORTY SEVENS STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, has been sent to all stockholders of Forty Seven at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement are available for free at the SEC's web site at http://www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Forty Seven. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Copies of the documents filed with the SEC by Forty Seven will be available free of charge under the Investors section of Forty Sevens internet website at ir.fortyseveninc.com.

Forward-Looking Statements:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expect, potential, plans, will, believe, and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing and outcome of results from the Phase 1b trial evaluating magrolimab in combination with azacitidine for the treatment of MDS and AML, the potentially-registration enabling clinical development program for magrolimab in higher-risk MDS, the single-arm, registration enabling trial evaluating the combination of magrolimab and rituximab in heavily pre-treated relapsed or refractory DLBCL patients, and other ongoing trials of 5F9 for the treatment of ovarian and colorectal cancer; the timing of and quality of results from investigational new drug-application enabling studies for FSI-189 and FSI-174 and their respective potential for approval by the FDA; the timing and success of research and development plans for Rockets and Forty Sevens respective platforms, product candidates and collaboration; the timing and success of research and development plans for bluebirds and Forty Sevens respective platforms, product candidates and collaboration; the business combination with Gilead and related matter; post-closing operations and the outlook for the companies respective businesses, including, without limitation, the ability of Gilead to advance Forty Sevens product pipeline, including magrolimab, FSI-174 and FSI-189; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; difficulties or unanticipated expenses in connection with integrating the companies; Forty Sevens ability to fund its clinical programs and the sufficiency of its cash and short-term investments, and Forty Sevens financial outlook; and any assumptions underlying any of the foregoing.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by such forward-looking statements include: the potential product candidates that Forty Seven develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or successfully commercialized; uncertainties as to the timing of the business combination with Gilead; the possibility that various closing conditions for the business combination may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of the business combination on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies periodic reports filed with the U.S. Securities and Exchange Commission (the SEC), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Forty Seven and the Schedule TO and related tender offer documents filed by Gilead and Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead and Forty Seven, and Gilead and Forty Seven assume no obligation and disclaim any intent to update any such forward-looking statements.

For more information please visit http://www.fortyseveninc.com or contactinfo@fortyseveninc.com.

For journalist enquiries please contact Sarah Plumridge atfortyseven@hdmz.comor phone (312) 506-5218.

For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. athannah.deresiewicz@sternir.comor phone (212) 362-1200.

Forty Seven Inc.Statements of Operations and Comprehensive Loss Data(In thousands, except share and per share data)

Forty Seven Inc.Selected Balance Sheet Data(in thousands)

Read the rest here:
Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights - BioSpace

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : Drivers, Restraints, Opportunities, and Threats (2019-2025) – Packaging News 24

By Stell Cell Research

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/18928?source=atm

For competitor segment, the report includes global key players of Platelet Rich Plasma and Stem Cell Alopecia Treatment as well as some small players.

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Request Sample Report @https://www.mrrse.com/sample/18928?source=atm

Important Key questions answered in Platelet Rich Plasma and Stem Cell Alopecia Treatment market report:

What will the market growth rate, Overview, and Analysis by Type of Platelet Rich Plasma and Stem Cell Alopecia Treatment in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Platelet Rich Plasma and Stem Cell Alopecia Treatment market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Platelet Rich Plasma and Stem Cell Alopecia Treatment market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

Buy This Report @ https://www.mrrse.com/checkout/18928?source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Platelet Rich Plasma and Stem Cell Alopecia Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Platelet Rich Plasma and Stem Cell Alopecia Treatment , with price, sales, revenue and global market share of Platelet Rich Plasma and Stem Cell Alopecia Treatment in 2019 and 2015.

Chapter 3, the Platelet Rich Plasma and Stem Cell Alopecia Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Platelet Rich Plasma and Stem Cell Alopecia Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Platelet Rich Plasma and Stem Cell Alopecia Treatment market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Platelet Rich Plasma and Stem Cell Alopecia Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the original:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : Drivers, Restraints, Opportunities, and Threats (2019-2025) - Packaging News 24

Disruptions in Cancer Care in the Era of COVID-19 – Medscape

By Stem Cell Medical Center

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Even in the midst of the COVID-19 pandemic, cancer care must go on, but changes may need to be made in the way some care is delivered.

"We're headed for a time when there will be significant disruptions in the care of patients with cancer," said Len Lichtenfeld, MD, deputy chief medical officer of the American Cancer Society (ACS), in a statement. "For some it may be as straightforward as a delay in having elective surgery. For others it may be delaying preventive care or adjuvant chemotherapy that's meant to keep cancer from returning or rescheduling appointments."

Lichtenfeld emphasized that cancer care teams are going to do the best they can to deliver care to those most in need. However, even in those circumstances, it won't be life as usual. "It will require patience on everyone's part as we go through this pandemic," he said.

"The way we treat cancer over the next few months will change enormously," writes a British oncologist in an article published in the Guardian.

"As oncologists, we will have to find a tenuous balance between undertreating people with cancer, resulting in more deaths from the disease in the medium to long term, and increasing deaths from COVID-19 in a vulnerable patient population. Alongside our patients we will have to make difficult decisions regarding treatments, with only low-quality evidence to guide us," writes Lucy Gossage, MD, consultant oncologist at Nottingham University Hospital, UK.

The evidence to date (from reports from China in Lancet Oncology) suggests that people with cancer have a significantly higher risk of severe illness resulting in intensive care admissions or death when infected with COVID-19, particularly if they recently had chemotherapy or surgery.

"Many of the oncology treatments we currently use, especially those given after surgery to reduce risk of cancer recurrence, have relatively small benefits," she writes.

"In the current climate, the balance of offering these treatments may shift; a small reduction in risk of cancer recurrence over the next 5 years may be outweighed by the potential for a short-term increase in risk of death from COVID-19. In the long term, more people's cancer will return if we aren't able to offer these treatments," she adds.

One thing that can go on the back burner for now is routine cancer screening, whichcan bepostponed for now in order to conserve health system resources and reduce contact with healthcare facilities, says the ACS.

"Patients seeking routine cancer screenings should delay those until further notice," said Lichtenfeld. "While timely screening is important, the need to prevent the spread of coronavirus and to reduce the strain on the medical system is more important right now."

But as soon as restrictions to slow the spread of COVID-19 are lifted and routine visits to health facilities are safe, regular screening tests should be rescheduled.

The American Society of Clinical Oncology (ASCO) has issued new guidance on caring for patients with cancer during the COVID-19 outbreak.

First and foremost, ASCO encourages providers, facilities, and anyone caring for patients with cancer to follow the existing guidelines from the Center for Disease Control and Prevention (CDC) when possible.

ASCO highlights the CDC's general recommendation for healthcare facilities that suggests "elective surgeries" at inpatient facilities be rescheduled if possible, which has also been recommended by the American College of Surgeons.

However, in many cases, cancer surgery is not elective but essential, it points out. So this is largely an individual determination that clinicians and patients will need to make, taking into account the potential harms of delaying needed cancer-related surgery.

Systemic treatments, including chemotherapy and immunotherapy, leave cancer patients vulnerable to infection, but ASCO says there is no direct evidence to support changes in regimens during the pandemic. Therefore, routinely stopping anticancer or immunosuppressive therapy is not recommended, as the balance of potential harms that may result from delaying or interrupting treatment versus the potential benefits of possibly preventing or delaying COVID-19 infection remains very unclear.

Clinical decisions must be individualized, ASCO emphasized, and suggestedthe following practice points be considered:

For patients already in deep remission who are receiving maintenance therapy, stopping treatment may be an option.

Some patients may be able to switch from IV to oral therapies, which would decrease the frequency of clinic visits.

Decisions on modifying or withholding chemotherapy need to consider both the indication and goals of care, as well as where the patient is in the treatment regimen and tolerance to the therapy. As anexample, the riskbenefit assessment for proceeding with chemotherapy in patients with untreated extensive small-cell lung cancer is quite different than proceeding with maintenance pemetrexed for metastatic nonsmall cell lung cancer.

If local coronavirus transmission is an issue at a particular cancer center, reasonable options may include taking a 2-week treatment break or arranging treatment at a different facility.

Evaluate if home infusion is medically and logistically feasible.

In some settings, delaying or modifying adjuvant treatment presents a higher risk of compromised disease control and long-term survival than in others, but in cases where the absolute benefit of adjuvant chemotherapy may be quite small and other options are available, the risk of COVID-19 may be considered an additional factor when evaluating care.

For patients who are candidates for allogeneic stem cell transplantation, a delay may be reasonable if the patient is currently well controlled with conventional treatment, ASCO comments. It also directs clinicians to follow the recommendations provided by the American Society of Transplantation and Cellular Therapy and from the European Society for Blood and Marrow Transplantation regarding this issue.

Finally, there is also the question of prophylactic antiviral therapy: Should it be considered for cancer patients undergoing active therapy?

The answer to that question is currently unknown, says ASCO, but "this is an active area of research and evidence may be available at any time."

For more from Medscape Oncology, join us on Twitter and Facebook.

Read this article:
Disruptions in Cancer Care in the Era of COVID-19 - Medscape

In vivo Comparison of the Biodistribution and Toxicity of InP/ZnS Quan | IJN – Dove Medical Press

By Stem Cell Medical Center

Li Li,1,2 Yajing Chen,1 Gaixia Xu,2,3 Dongmeng Liu,1 Zhiwen Yang,1 Tingting Chen,1 Xiaomei Wang,1 Wenxiao Jiang,1 Dahui Xue,1 Guimiao Lin1

1Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, Shenzhen Key Laboratory of Synthetic Biology, Department of Physiology, School of Basic Medical Sciences, Shenzhen University, Shenzhen 518055, Peoples Republic of China; 2Key Laboratory of Optoelectronics Devices and Systems of Ministry of Education/Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, Peoples Republic of China; 3Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518055, Peoples Republic of China

Correspondence: Guimiao LinSchool of Basic Medical Sciences, Shenzhen University Health Sciences Center, Shenzhen 518060, Peoples Republic of ChinaTel/ Fax +86-755-86671903Email gmlin@szu.edu.cn

Introduction: Indium phosphide (InP) quantum dots (QDs) have shown a broad application prospect in the fields of biophotonics and nanomedicine. However, the potential toxicity of InP QDs has not been systematically evaluated. In particular, the effects of different surface modifications on the biodistribution and toxicity of InP QDs are still unknown, which hinders their further developments. The present study aims to investigate the biodistribution and in vivo toxicity of InP/ZnS QDs.Methods: Three kinds of InP/ZnS QDs with different surface modifications, hQDs (QDs-OH), aQDs (QDs-NH2), and cQDs (QDs-COOH) were intravenously injected into BALB/c mice at the dosage of 2.5 mg/kg BW or 25 mg/kg BW, respectively. Biodistribution of three QDs was determined through cryosection fluorescence microscopy and ICP-MS analysis. The subsequent effects of InP/ZnS QDs on histopathology, hematology and blood biochemistry were evaluated at 1, 3, 7, 14 and 28 days post-injection.Results: These types of InP/ZnS QDs were rapidly distributed in the major organs of mice, mainly in the liver and spleen, and lasted for 28 days. No abnormal behavior, weight change or organ index were observed during the whole observation period, except that 2 mice died on Day 1 after 25 mg/kg BW hQDs treatment. The results of H&E staining showed that no obvious histopathological abnormalities were observed in the main organs (including heart, liver, spleen, lung, kidney, and brain) of all mice injected with different surface-functionalized QDs. Low concentration exposure of three QDs hardly caused obvious toxicity, while high concentration exposure of the three QDs could cause some changes in hematological parameters or biochemical parameters related to liver function or cardiac function. More attention needs to be paid on cQDs as high-dose exposure of cQDs induced death, acute inflammatory reaction and slight changes in liver function in mice.Conclusion: The surface modification and exposure dose can influence the biological behavior and in vivo toxicity of QDs. The surface chemistry should be fully considered in the design of InP-based QDs for their biomedical applications.

Keywords: InP/ZnS quantum dots, surface chemistry, in vivo, biodistribution, nanotoxicology

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See more here:
In vivo Comparison of the Biodistribution and Toxicity of InP/ZnS Quan | IJN - Dove Medical Press

→←